To investigate the clinical efficacy and potential mechanisms, including immune response modulation, of PD-1 inhibitors combined with chemotherapy and targeted therapy in ovarian cancer patients with brain metastases.
Key Findings:
The patient with a single brain metastasis achieved complete response (CR) after comprehensive treatment and prolonged progression-free survival, highlighting the potential of targeted therapies.
The patient with multiple brain metastases showed significant short-term efficacy but died due to complications, underscoring the challenges in treating advanced disease.
Higher expression of CD4, CD8, CD31, and PD-L1 was observed in brain metastases compared to the primary tumor, indicating increased T-cell infiltration and potential for enhanced immune response.
Gene testing confirmed HRD positivity in the patient with a single brain metastasis, and maintenance therapy with a PARP inhibitor combined with a PD-1 inhibitor was effective.
Interpretation:
PD-1 inhibitors combined with chemotherapy and targeted therapy may offer a new treatment option for ovarian cancer patients with brain metastases, particularly those with a single brain metastasis, suggesting a need for further exploration of treatment strategies.
Limitations:
The study is based on a small sample size of only two patients, limiting the generalizability of the findings.
The prognosis for patients with multiple brain metastases remains poor.
Conclusion:
Further research is needed to explore the correlation between peripheral blood immune markers and treatment response in brain metastases.
